Merck KGaA Add to portfolio

DAXX:MRK, May 29, 10:40 UTC

Latest DAXX:MRK News

Filter your feed

Apply Filter

Tuesday, May 26


News

Novavax, Merck rise; Regeneron, Anaplan fall

MRK ANA

NEW YORK (AP) — Stocks that moved heavily or traded substantially on Tuesday: Novavax, Merck rise; Regeneron, Anaplan fall. The auto parts retailer handily beat Wall Street's fiscal third-quarter profit and revenue forecasts. The bank terminated a merger deal with Texas Capital Bancshares because of a significant impact from the virus pandemic. The drug developer is buying back $5 billion of its stock as Sanofi sells a majority of its stake in the company.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Tuesday, May 19


News

CORRECTING and REPLACING Merck Announces Appointment of Organon & Co. Chief Financial Officer and Chief Information Officer

MRK

Third paragraph, end of fourth sentence of release dated May 18, 2020, should read: including Syneos Health / Inventiv Health and Optimer Pharmaceuticals (instead of including Pfizer, Syneos Health / Inventiv Health and Optimer Pharmaceuticals). In his new role at Organon, Matt will be responsible for the development and execution of the company’s overall financial strategy, and will oversee corporate financial planning, tax, audit, treasury, investor relations and business development. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases – as we aspire to be the premier research-intensive biopharmaceutical company in the world. For more information, visit www.merck.com and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn. Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Read Full Details

Topics:
  • Business
  • Health
  • Science
  • Financial

Tuesday, May 12


News

Outlook on the Worldwide Hepatitis C Drugs Industry to 2025 - Featuring Abbvie, Gilead Sciences, Merck & Co & Bristol-Myers Squibb Among Others

MRK GILD

This is mainly caused by sharing needles, unsterilized medical equipment, and a blood transfusion from infected mothers to newborn babies. As per the research analysis, the Global Hepatitis C Drugs Market would be US$ 5.9 Billion by 2025.In recent years, several drugs have been launched due to the high prevalence of Hepatitis C across the globe. Mavyret has several advantages compared to other drugs such as its treatment course is shorter, and it is much cheaper. Harvoni drugs are popular in India, and it's easier affordable among the public.Oral injections and dosages are required weekly in Hepatitis C; at the same time, its side effects can lead to permanent damage of other organs of patients. The market share of Asia - Pacific's and Latin American regions will grow during the forecast period.The report titled Hepatitis C Drugs Market Global Forecast by Drugs (Mavyret, Viekira Pak, Harvoni, Epclusa, Sovaldi, Vosevi, Zepatier, Others), Distribution Channels (Hospital Pharmacies, Retail Pharmacies, Online Pharmacy), Regions (North America, Europe, Asia Pacific, Latin America, Middle East & Africa), Company Analysis (Abbvie, Gilead Sciences, Merck, Bristol-Myers Squibb, Others) provides a complete analysis Hepatitis C market globally.Mavyret is the leading drug in the global hepatitis C marketComplete analysis of 7 drugs Mavyret, Viekira Pak, Harvoni, Epclusa, Sovaldi, Vosevi, Zepatier, Others is given in the report.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
  • Entertainment

Friday, May 08


News

Merck Announces Virtual 2020 Annual Shareholders Meeting

MRK

Guests may also access the virtual Annual Meeting but in listen-only mode. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2019 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

Read Full Details

Topics:
  • Business
  • Health
  • Science

Wednesday, April 29


News

The Daily Biotech Pulse: Inovio's MERS Vaccine Data, Fast Track Designation For Erytech, FDA Approves Higher Dose Of Merck's Keytruda

MRK AZN +1 more MRK AZN AZN

Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO). REDHILL BIOPHAR/S ADR (NASDAQ: RDHL) (announced addition of its Talicia, meant to treat H. pylori infection, to Prime Therapeutics NetResults A-Series National Formulary). "As we have designed our COVID-19 vaccine INO-4800 using the same strategy as INO-4700, including the selection of full length Spike protein as the target and the use of intradermal CELLECTRA device, we are hopeful that the ongoing Phase 1 clinical trial with INO-4800 would generate similar clinical immune responses and safety data as we have just reported for INO-4700," CEO Dr. Joseph Kim said in a statement. Supernus Pharmaceuticals Inc (NASDAQ: SUPN) announced a definitive agreement under which it will acquire the CNS portfolio of US WorldMeds, a privately held biopharmaceutical company, for an upfront payment of $300 million, plus cash milestone payments of up to $230 million.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Tuesday, April 28


News

D.R. Horton, 3M rise; Merck, Centene fall – The Seattle Times

MRK MMM +2 more MRK MMM CNC DHI

NEW YORK (AP) — Stocks that moved heavily or traded substantially on Tuesday:. The homebuilder reported surprisingly good fiscal second-quarter profits and revenue. The maker of Post-it notes, masks and respirators reported a jump in first-quarter revenue and its financial results beat analysts’ forecasts. The food and beverage company reported an increase in first-quarter revenue and its earnings beat Wall Street forecasts.

Read Full Details

Topics:
  • Business
  • Financial
News

Merck (MRK) Q1 Earnings and Revenues Top Estimates

MRK

Over the last four quarters, the company has surpassed consensus EPS estimates four times. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Merck was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future.

Read Full Details

Topics:
  • Business
  • Financial
News

Merck Announces First-Quarter 2020 Financial Results

MRK

In the first quarter, within our human health business, markets in Asia Pacific, including China, saw a negative impact from social distancing measures and reduced access to health care providers given the earlier prevalence of the virus; whereas other markets, particularly in Europe, saw customers build inventory due to concerns about supply and ability to access health care providers given social distancing measures. Operating expenses were positively impacted in the first quarter by approximately $100 million, primarily driven by lower promotional and selling costs and delayed clinical program spending due to COVID-19. For the full-year 2020, Merck expects a favorable impact to operating expenses of approximately $400 million. While the company expects to rely on governmental authorities to determine when operations can return to normal and is cognizant that the duration, spread and severity of the outbreak will be critical determinants, for the purposes of the full-year estimates provided above, the company has assumed the majority of the negative impact will be in the second quarter, with a gradual return to normal operations beginning late in the second quarter and extending through the third quarter, with a full return to normal operations in the fourth quarter. Merck’s financial strength and strong balance sheet is allowing it to continue with its capital allocation priorities, including investing in research and development (R&D) and in growth drivers, investing in manufacturing capacity expansion, paying its dividend and continuing the search for value-enhancing business development. However, given these priorities and the current operating environment, Merck has temporarily suspended its share repurchase program. We are actively supporting communities in various ways, including through product donations, personal protective equipment (PPE) donations and funding to relief organizations, including the United Nations Foundation’s COVID-19 Solidarity Response Fund in support of the World Health Organization and to the U.S. Centers for Disease Control and Prevention (CDC) Foundation Emergency Response Fund.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

D.R. Horton, 3M rise; Merck, Centene fall

MRK MMM +2 more MRK MMM CNC DHI

NEW YORK (AP) — Stocks that moved heavily or traded substantially on Tuesday:. The homebuilder reported surprisingly good fiscal second-quarter profits and revenue. The maker of Post-it notes, masks and respirators reported a jump in first-quarter revenue and its financial results beat analysts’ forecasts. The food and beverage company reported an increase in first-quarter revenue and its earnings beat Wall Street forecasts.

Read Full Details

Topics:
  • Business
  • Financial

Monday, April 20


News

Cue Biopharma Announces Clinical Trial Collaboration Agreement with Merck to Evaluate CUE-101 in Combination with KEYTRUDA® (pembrolizumab) as First-line Treatment For HPV+ Recurrent/Metastatic Head and Neck Cancer Nasdaq:CUE

MRK

“We are very pleased to collaborate in this important study with Merck, an established leader in cancer immunotherapy, with our first clinical asset, CUE-101, which represents our IL-2 variant CUE-100 Series,” said Daniel Passeri, chief executive officer of Cue Biopharma. “Through the monotherapy and combination studies, we believe we will be able to demonstrate the mechanistic advantages of our approach and platform for modulating disease-relevant T cells directly in the patient’s body to safely enhance efficacy over current standards of care.”“Immunotherapies have revolutionized the treatment of patients with certain types of cancers. However significant unmet need remains – particularly in those individuals who do not respond or develop resistance to checkpoint therapy,” said Ken Pienta, M.D, acting chief medical officer of Cue Biopharma. “Based on a novel mechanism of action designed to induce and expand tumor-specific T cells in the patient’s body, we believe CUE-101 may lead to enhanced anti-tumor activity in combination with KEYTRUDA.”. The article titled, CUE-101, a Novel HPV16 E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen Specific T Cell Activation for the Treatment of HPV16-Driven Malignancies, includes CUE-101 data that demonstrate selective binding, activation and expansion of HPV16-specific, disease-relevant, T cells.

Read Full Details

Topics:
  • Business
  • Health
  • Technology
  • Financial